Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is the purchase of ordinary shares by five individuals on November 4, 2011. These purchases resulted from the reinvestment of dividends on shares held within Individual Savings Accounts (ISAs). The transaction price was 1,388.995 pence per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Dividend reinvestment (DRIP) within ISAs.
- Transaction Date: November 4, 2011.
- Share Price: 1,388.995 pence per share.
- Directors Involved:
- Mr A P Witty: 24 shares
- Mr S M Bicknell: 67 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
- Mrs V A Whyte: 13 shares
- Notification Date: November 7, 2011.